Clinical Trials Logo

Narcolepsy clinical trials

View clinical trials related to Narcolepsy.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06413420 Recruiting - Clinical trials for Obstructive Sleep Apnea

SUNOSI® (Solriamfetol) Pregnancy Registry

Start date: July 31, 2019
Phase:
Study type: Observational [Patient Registry]

The SUNOSI (solriamfetol) Pregnancy Registry is a prospective, multi-country, observational study to evaluate the safety of solriamfetol exposure during pregnancy in women with a diagnosis of narcolepsy or obstructive sleep apnea (OSA).

NCT ID: NCT06358950 Recruiting - Narcolepsy Type 1 Clinical Trials

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

Vibrance-1
Start date: March 28, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.

NCT ID: NCT06336057 Recruiting - Narcolepsy Type 1 Clinical Trials

Mentalizating in Adults Suffering From Narcolepsy Type 1.

NARCOMENTAL
Start date: April 2024
Phase:
Study type: Observational

The main objective is to examine the potential mentalization impairments affecting a population suffering from narcolepsy type 1. Indeed, the hypothesis of this research is that mentalization could be impaired in narcoleptic patients.

NCT ID: NCT06279247 Recruiting - Narcolepsy Clinical Trials

Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy

Start date: September 1, 2022
Phase:
Study type: Observational

Narcolepsy (NRL) is a rare chronic central nervous system dysfunction disease, which is more common in children and adolescents, and less common in adults. Its typical clinical features include excessive daytime sleep, paroxysmal cataplexy, sleep paralysis and sleep hallucination. In addition to the above typical manifestations, patients with narcolepsy can also manifest as hyperappetite, weight gain, multiple dreams, sleep fragmentation, anxiety and depression and other emotional disorders. In particular, in narcolepsy type 1 with cataplexy, cataplexy episodes can be confused with falls caused by seizures, transient ischemic attacks or neuromuscular disorders, or even mental conversion disorders. Due to its diverse clinical symptoms, it is easy to be missed and misdiagnosed. At present, the pathogenesis of narcolepsy is still unclear, and its pathogenesis may be related to immune, genetic, environmental, infection, central nervous system degeneration and other factors. This study aims to investigate the changes of body fluid proteomics and metabolomics in patients with narcolepsy, and to provide an important basis for the pathogenesis of narcolepsy.

NCT ID: NCT06251063 Recruiting - Clinical trials for Idiopathic Hypersomnia

Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to test a web-based psychoeducational resource for adolescents with central disorders of hypersomnolence and their families. The investigators hope to assess the website's usability, acceptability, and feasibility, as well as its potential effect on social relationship health. Participants will be asked to review the content of the psychoeducational websites. The participants will then provide feedback on the website, as well as the adolescent's social relationships and social health before and after reviewing the website through online surveys.

NCT ID: NCT06179407 Recruiting - Narcolepsy Clinical Trials

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

Start date: January 24, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). Part 1 will evaluate safety, tolerability, and PK of MK-6552 after administration of ascending doses in a single day to support a dose level decision for Part 2. Part 2 will investigate the PD of MK-6552 after single-day and multiple-day administration. Participants who complete Part 1 and demonstrate that they are able to tolerate at least one dose level of MK-6552 will participate in Part 2.

NCT ID: NCT05967832 Recruiting - Narcolepsy Type 1 Clinical Trials

Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy

NARCO7T
Start date: January 29, 2024
Phase: N/A
Study type: Interventional

This study is part of the research on type 1 narcolepsy, a neurological pathology affecting mostly young subjects. The only biomarker currently available is the hypocretin assay, which shows a level below 110 pg/mL. However, the interpretation of this biomarker has limitations: the test is not widely available and it is rarely performed by practitioners. Even when performed, the interpretation of the level may not be consistent with the phenotype compatible with type 1 narcolepsy. This study therefore aims to develop new tools to reduce the diagnostic delay. This would be the first study with 7T MRI that could achieve a level of spatial resolution sufficient to highlight volume changes in small brain structures such as the lateral hypothalamus whose narcolepsy-induced changes are not detected by lower resolution MRI.

NCT ID: NCT05884112 Recruiting - Narcolepsy Clinical Trials

Treating Comorbid Depression of Patients With Narcolepsy by Intermittent Theta Burst Stimulation

Start date: February 22, 2023
Phase: N/A
Study type: Interventional

Narcolepsy is a chronic brain disorder. The mechanism is the impairment of brain controlling of sleep and wakefulness. The cause of this disease is still unclear, but common symptoms include excessive day time sleepiness, cataplexy, hypnogogic hallucination, sleep paralysis, and sleep disturbance. Because these symptoms are easily confused together in many situations, it is difficult for doctors to make the diagnosis. Therefore, medical treatment for patients is always delayed. According to previous research report, narcoleptic patients are often delay diagnosis for 10 to 15 years after the onset of the disease. Clearly, to make the diagnosis of narcolepsy is very difficult. Another cause for the delay is the method for diagnosing narcolepsy, which mainly rely on sleep examination instruments and the testing of hypocretin concentration in the cerebrospinal fluid. However, these tests are difficult to carry out in many areas, and diagnosing narcolepsy is still difficult in many countries. To the patients and their families, developing a fast and accurate method or tool for diagnosing narcolepsy is of the utmost importance.

NCT ID: NCT05875974 Recruiting - Narcolepsy Clinical Trials

Ph4 PSG Combined JZP258-407

Start date: July 27, 2023
Phase: Phase 4
Study type: Interventional

This study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic hypersomnia (IH) or narcolepsy.

NCT ID: NCT05869773 Recruiting - Narcolepsy Clinical Trials

A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy

Start date: June 26, 2023
Phase: Phase 4
Study type: Interventional

The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.